Home › All Companies › CNTX

Context Therapeutics Inc. (CNTX)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-06

Key Insights

  • Context Therapeutics is a clinical-stage biopharmaceutical company with multiple pipeline programs (CTIM76, CT95, CT202) in development, indicating diversified R&D efforts across oncology and other therapeutic areas.
  • The company maintains collaborative arrangements with strategic partners including BioAtla Inc. and Lonza, suggesting external validation and potential cost-sharing mechanisms for development programs.
  • As a smaller reporting company and emerging growth company, CNTX has reduced disclosure requirements and regulatory flexibility, typical for early-stage biotech firms with limited operational scale.
  • The filing shows multiple financing activities including at-the-market (ATM) facility usage and private placements, indicating ongoing capital raising needs to fund operations and clinical development.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-05-01

Key Insights

  • Delaware Court invalidated the company's multi-class board structure, eliminating three-year director terms and the removal-for-cause-only provision, making the board more responsive to shareholder pressure and increasing governance accountability.
  • A third-party service provider agreed to cover the full $850,000 mootness fee on behalf of the company, eliminating material legal costs that would have otherwise impacted cash reserves and demonstrating support from a strategic partner.
  • The stockholder class action lawsuit has been substantially resolved with only the formality of confirming a quorum at the June 24, 2026 annual meeting remaining, providing clarity and removing litigation overhang for investors.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-04-02

Key Insights

  • Context Therapeutics Inc. has received Fast Track designation from the FDA for its investigational drug CTIM-76, which targets platinum-resistant ovarian cancer, indicating the potential for an accelerated development and review process.
  • The Fast Track designation highlights the unmet medical need in this patient population and the potential of CTIM-76 to address this need, which could be a significant development for the company.
  • Successful development and approval of CTIM-76 could provide a new treatment option for patients with platinum-resistant ovarian cancer, a difficult-to-treat condition with limited therapeutic options.
Sentiment: Positive Significance: 8/10
View Original Filing →
Annual Report Filed: 2026-03-23

Key Insights

  • Context Therapeutics is developing a pipeline of antibody-based therapies, including CTIM76, CT95, and CT202, with potential to address various oncology indications.
  • The company has secured financing through private placements and at-the-market offerings, providing capital to fund its research and development activities.
  • Context Therapeutics has entered into collaborative agreements with Integral Molecular Inc. and BioAtla Inc. to advance its pipeline, potentially unlocking additional value for shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-03-23

Key Insights

  • Context Therapeutics Inc. filed an 8-K report on March 23, 2026, which included an updated corporate presentation for investor meetings.
  • The presentation provided additional details on the company's business and pipeline, with notable slides incorporated by reference.
  • As an emerging growth company, Context Therapeutics may be taking advantage of certain financial reporting and disclosure exemptions.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-03-13

Key Insights

  • The company's certificate of incorporation was amended, removing provisions that required directors to serve 3-year terms and could only be removed for cause. This will allow for more flexibility in director elections and removals.
  • The company intends to propose director nominees for 1-year terms at the upcoming annual meeting, rather than the previous 3-year terms.
  • A stockholder lawsuit against the company was dismissed with prejudice, though the court retains jurisdiction for any mootness fee application.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-27

Key Insights

  • Context Therapeutics filed a stipulation and proposed consent judgment with the Delaware Court of Chancery regarding a stockholder class action complaint. If approved, the court will invalidate certain provisions in the company's charter related to staggered board terms and removal of directors only for cause.
  • The company intends to hold its 2026 annual meeting of stockholders on June 24, 2026, with a record date of April 27, 2026, and will include a proposal to elect directors to one-year terms.
  • Stockholders wishing to submit proposals or nominate directors for the annual meeting must provide notice to the company's secretary by March 14, 2026, in accordance with the company's bylaws.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-02-23

Key Insights

  • The reporting person, Martin A. Lehr, acquired 815,000 stock options in Context Therapeutics Inc. (CNTX) on February 19, 2026, indicating strong management confidence in the company's future prospects.
  • The stock options have a strike price of $2.32 and a 10-year expiration date, suggesting a long-term investment horizon for the reporting person.
  • The options vest over a 4-year period, aligning the reporting person's incentives with long-term shareholder value creation.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-02-23

Key Insights

  • Karen Deborah Chagin, the Chief Medical Officer of Context Therapeutics Inc. (CNTX), has been granted a stock option to acquire 290,000 shares of the company's common stock, vesting over a four-year period.
  • The exercise price of the stock option is $2.32 per share, which could potentially provide Chagin with a financial incentive to drive the company's growth and performance.
  • As an officer of the company, Chagin's stock option acquisition could be seen as a positive signal of management's confidence in the company's future prospects.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-23

Key Insights

  • Jennifer Lynn Minai-Azary, the Chief Financial Officer of Context Therapeutics Inc. (CNTX), has been granted a stock option of 275,000 shares, vesting over a four-year period.
  • This insider transaction indicates the company's commitment to incentivizing its leadership team and aligning their interests with those of shareholders.
  • The timing of this grant, close to the company's financial reporting period, suggests it may be part of the company's regular compensation practices.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-23

Key Insights

  • Alex C. Levit, the Chief Legal Officer and Corporate Secretary of Context Therapeutics Inc., has received a stock option grant of 270,000 shares with an exercise price of $2.32.
  • The option vests over a four-year period, with 25% vesting on February 19, 2027, and the remaining balance vesting in equal monthly installments over the following three years.
  • This stock option grant suggests that Levit is incentivized to remain with the company and contribute to its long-term success.
Sentiment: Positive Significance: 4/10
View Original Filing →
Current Report Filed: 2026-01-08

Key Insights

  • Context Therapeutics Inc. has updated its corporate presentation for use in meetings with investors, analysts and others, providing an opportunity for the company to share its latest developments and plans.
  • The filing does not indicate any material new agreements, leadership changes or earnings surprises, suggesting this is a routine corporate update rather than a significant event.
  • As an emerging growth company, Context Therapeutics may have additional flexibility in complying with new or revised financial accounting standards.
Sentiment: Neutral Significance: 3/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.